Oral Immunotherapy for the Treatment of Chronic Diseases and Infections

Abstract

For the last 20 years, the group-specific component (Gc) protein-derived Macrophage Activating Factor (GcMAF), has received a lot of attention. In 1999, the Japanese researcher Nobuto Yamamoto published his first report mentioning the use of Gc -MAF on Tumour Bearing Mice, along with another group the same year. It has received a great deal of attention in the past few years because of its proposed therapeutic use in the immunotherapy of cancer and other diseases ranging from autism and AIDS to multiple sclerosis and lupus.